ArticleScientific reports2025
Metabolic dysfunction impairs Mycobacterium tuberculosis-specific cytokine and chemokine responses in latent tuberculosis and type 2 diabetes mellitus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis.Frontiers in endocrinology · 2026Pooled it
- Immune Checkpoint Inhibitors in Cancer Patients With Concurrent Active Tuberculosis: A Real-World Study in a High Tuberculosis Burden Region.Open forum infectious diseases · 2026Article
- Development and validation of a nomogram for predicting unfavorable treatment outcomes in patients with pulmonary tuberculosis and diabetes mellitus.Frontiers in medicine · 2026Article
- A quadral biosignature of IFN-γ, IL-2, IL-12 and IP-10 increases the diagnostic potential for latent tuberculosis among diabetic patients in Uganda.BMC immunology · 2025Article
- Immune Response to TB Antigen Stimulation in Type 2 Diabetes Mellitus: Insights from a Cross-Sectional Cytokine Profile Analysis.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (DM) is associated with impaired host immune responses, increasing the risk for latent tuberculosis (TB) infection (LTBI). This study investigated how DM and associated metabolic dysfunction alter Mycobacterium tuberculosis (Mtb)-specific cytokine and chemokine responses. We analysed a cohort of 164 participants with and without DM and/or LTBI. Mtb-specific cytokine/chemokine responses were measured in QuantiFERON-TB Gold-Plus supernatants using a 17-plex Luminex assay to quantify Th1, Th2, Th17, inflammatory and regulatory responses. DM was associated with decreased Mtb-specific IFN-γ, TNF, IL-12, IP-10 and MIP-1α, with increased IFN-α compared to non-DM, suggesting impairment of Th1 and inflammatory pathways. Additionally, pre-DM was not associated with altered cytokine/chemokine responses, but subtle changes in IL-10, GM-CSF, MIP-1β, and IL-1β may suggest early indicators of immune dysregulation. Poorly controlled DM was associated with increased IL-4 and IFN-α, indicating a shift toward Th2 and inflammatory responses. Compared to borderline high, high total cholesterol levels, indicating dyslipidaemia, were associated with decreased IFN-γ, TNF and IL-2, suggesting impaired Th1 immunity. These findings imply that metabolic disturbances may compromise Mtb-specific immune responses, potentially increasing TB infection susceptibility. Optimising glycaemic and lipid control may be crucial for restoring immune balance and improving TB outcomes in patients with DM-associated metabolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.